Widely used:Recently Viewed
Clear All$8.58
$0.31
(3.75%)
As on 24-Apr-2025 16:00EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$566 Mln
P/E Ratio
--
P/B Ratio
2.6
Industry P/E
--
Debt to Equity
0
ROE
-0.05 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$264.39 Mln
EBITDA
$230.05 Mln
Net Profit
$-6.26 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Pharming Group N.V. ADS each representing 10 (PHAR)
| -14.75 | -2.89 | -7.64 | -10.63 | -0.15 | -- | -- |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Pharming Group N.V. ADS each representing 10 (PHAR)
| -11.85 | 3.63 | 23.38 | -41.16 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 546.78 | 8,556.32 | 29.41 | 27.8 |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is... RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. Address: Darwinweg 24, Leiden, Netherlands, 2333 CR Read more
President, CEO & Executive Director
Dr. Sijmen de Vries M.B.A., M.D.
President, CEO & Executive Director
Dr. Sijmen de Vries M.B.A., M.D.
Headquarters
Leiden
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Pharming Group NV ADS each representing 10 (PHAR) stood at $ 678 Mln as on 31-Mar-25
The share price of Pharming Group NV ADS each representing 10 (PHAR) is $8.58 (NASDAQ) as of 24-Apr-2025 16:00 EDT. Pharming Group NV ADS each representing 10 (PHAR) has given a return of -0.15% in the last 3 years.
Pharming Group NV ADS each representing 10 (PHAR) has a market capitalisation of $ 566 Mln as on 24-Apr-2025. As per Value Research classification, it is a company.
The P/B ratio of Pharming Group NV ADS each representing 10 (PHAR) is 2.60 times as on 24-Apr-2025, a 13% premium to its peers’ median range of 2.30 times.
Since, TTM earnings of Pharming Group NV ADS each representing 10 (PHAR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Pharming Group NV ADS each representing 10 (PHAR) and enter the required number of quantities and click on buy to purchase the shares of Pharming Group NV ADS each representing 10 (PHAR).
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. Address: Darwinweg 24, Leiden, Netherlands, 2333 CR
The CEO & director of Dr. Sijmen de Vries M.B.A., M.D.. is Pharming Group NV ADS each representing 10 (PHAR), and CFO & Sr. VP is Dr. Sijmen de Vries M.B.A., M.D..
There is no promoter pledging in Pharming Group NV ADS each representing 10 (PHAR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
850
|
| Pharming Group N.V. ADS each representing 10 (PHAR) | Ratios |
|---|---|
|
Return on equity(%)
|
1.56
|
|
Operating margin(%)
|
2.53
|
|
Net Margin(%)
|
1.04
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Pharming Group NV ADS each representing 10 (PHAR) was $0 Mln.
